fbpx

molecules of the month

JNJ-64619178

pseudo-irreversible methyltransferase inh.

oral, phase I, cancer

from adenosine derivative library + opt.

Molecular Cancer Therapeutics

Janssen R&D

Chemical structure of molecule JNJ-64619178
1 min read

The Janssen PRMT5 inhibitor, onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with high selectivity and potency (subnanomolar range, PRMT5-MEP-50 IC50=0.14 nM) under various conditions. While JNJ-64619178 binds non-covalently in the PRMT5 SAM and substrate-binding sites evidenced by co-crystallography (PDB: 6RLQ), the molecule has a long-residence time, leading to sustained inhibition of PRMT5 even after short compound exposure. Interestingly, PD was observed for 6 days after treatment cessation, and comparable efficacy was observed with continuous daily dosing as in 7 d on, 7 d off cycles. Since PRMT5-dependent methylation events are reversed only by turnover of substrate proteins rather than by demethylases and PRMT5 itself has a long half-life, PRMT5 inhibitors with a long residence time…


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: